

PATENT  
0459-0636P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: LAURSEN, Inga et al. Conf.: 8992  
Appl. No.: 09/902,174 Group: 1644  
Filed: July 10, 2001 Examiner: SAUNDERS, D.  
For: PROCESS FOR PRODUCING IMMUNOGLOBULINS  
FOR INTRAVENOUS ADMINISTRATION AND  
OTHER IMMUNOGLOBULIN PRODUCTS

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION AFTER FILING OF AN APPLICATION  
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE  
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 13, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

a.  This application was filed before June 30, 2003. Accordingly, submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed. \*\*

b.  This application was filed on or after June 30, 2003. Accordingly, copies of cited U.S. patents and patent application publications therefore are not included. Copies of foreign

Appl. No. 09/902,174

patent documents and non-patent literature are included.

- c.  Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

\*\* This IDS is being fax filed concurrent with the filing of an RCE. But because of the size and number of cited references, only one of the references is being filed via facsimile and the remainder of the references will be hand carried to the USPTO.

**III. CONCISE EXPLANATION OF THE RELEVANCE**  
(check at least one box)

a.  DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b.  DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

The Reference(s):

- GAMMAGARD<sup>®</sup> S/D contains - an English Translation is attached.
- WO 94/29334 - contains an English Abstract on the first page of the patent.
- DE3430320 - attached is an English Abstract.

c.  ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d.  OTHER

The following additional information is provided for the Examiner's consideration.

FEES

- IV.  THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b) :  
(check one box)
- a.  within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.)
- b.  within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c.  concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d.  before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.  
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
- V.  THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c) :  
(check one box)
- before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).
- a.  No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).  
or
- b.  See the statement below. No fee is required.

Appl. No. 09/902,174

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a.  each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b.  each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c.  no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d.  Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.



Sheet 1 of 2 (9/13/04)

Form PTO-1449		ATTY. DOCKET NO. 0459-0636P	APPLICATION NO. 09/902,174		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <small>(Use several sheets if necessary)</small>		APPLICANT LAURSEN, Inga et al.			
		FILING DATE July 10, 2001	GROUP 1644		
<b>U.S. PATENT DOCUMENTS</b>					
EXAMINER INITIAL	DOCUMENT NUMBER	KIND	DATE	NAME	CLASS SUB CLASS FILING DATE IF APPROPRIATE
	US 5,164,487		1992-11-17	Kothe et al.	
	US 6,069,236		2000-05-30	Burnouf-Radosevich et al.	
	US 5,593,675		1997-01-14	Hodler et al.	
	US 5,177,194		1993-01-05	Sarno et al.	
	US 5,886,154		1999-03-23	Lebing et al.	
	US 08/997,952		1997-12-24	RAJA R. MAMIDI	
	US				
<b>FOREIGN PATENT DOCUMENTS</b>					
Office	DOCUMENT NUMBER	KIND	DATE	COUNTRY	CLASS SUB CLASS TRANSLATION YES NO
DE	3430320		1998-03-25	GERMANY	
AU	199870099	A1	1998-12-24	AUSTRALIA	
AU	747893		1999-07-19	AUSTRALIA	
WO	94/29334	A1	1994-12-22	PCT	
<b>OTHER DOCUMENTS</b> (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)					
	Vandersande, J. "Current Approaches to the Preparation fo Plasma Fractions," Biotechn., 1991, vol. 19: 165-176.				
	Page, M. et al., "IgG Purification," Methods in Mol. Biol, 1998, vol. 80: 95-111.				
	Doonan, S. "Protein Purification Protocols," Methods in Molecular Biology, Vol. 59: 164-165, 179, 401.				
	HARLOW et al., "Storing and Purifying antibodies," Antibodies - A Laboratory Manual, 1998, 283-318.				
EXAMINER		DATE CONSIDERED			
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with 37 C.F.R. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>					

LRS/KR/abp

FORM PTO-1449		ATTY. DOCKET NO. 0459-0636P	APPLICATION NO. 09/902,174
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		APPLICANT LAURSEN, Inga et al.	
		FILING DATE July 10, 2001	GROUP 1644

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	KIND	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

### FOREIGN PATENT DOCUMENTS

Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published).

	STEVENS, L., "Buffers," Labfax, Bios Scientific Publ. Ltd., Oxford, UK, 1996: 21-26.
	PRICE, N.C., "The Determination of Protein Concentration," Labfax, Bios Scientific Publ. Ltd., Oxford, UK, 1996: 33-63.
	GAMMAGARD® S/D, Product Information from February 1994, Baxter Deutschland GmbH, Edisonstr. 3-4, D-85716 Unterschleissheim.
	NOURICHAFI, N. et al., "Comparison of various chromatographic..," Biotechnology of Blood Proteins, 1993, vol. 227: 207-212.
	ANDERSON et al., "An improved chromatography method..," XXII Congress of the International Society of Blood Transfusion, Amsterdam, the Netherlands, 1994, July 2-8. Published by Pharmacia Biotech AB, S-75182 Uppsala SWEDEN
	Page et al., "Preparation of Purified Immunoglobulin G (IgG)," Methods in Molecular Biology, vol. 32, 1994: 407-431.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.R. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LRS/KR/680

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**